Clinical Observation Of Buyang Huanwu Decoction Combined With Osimertinib In The Treatment Of Brain Metastasis Of Lung Adenocarcinom

Objective: By observing the clinical efficacy and safety of Buyang Huanwu decoction combined with Osimertinib in the treatment of brain metastases(BM)patients with lung adenocarcinoma,more diagnosis and treatment solutions are provided for the combination of traditional Chinese and Western medicine in the treatment of patients with lung adenocarcinoma BM.Methods: A total of 60 patients with lung adenocarcinoma BM who met the diagnostic criteria and case criteria were selected and treated in the inpatient department of the Oncology Department of the First Affiliated Hospital of Hunan University of Chinese Medicine from December 2021 to January 2023,and were divided into treatment group(Buyang Huanwu decoction combined with Osimertinib)and control group(Osimertinib monotherapy)according to the random number table method(there was no significant difference in gender,age,smoking history,extracranial metastases,and number of brain metastases between the two groups).The two groups were limited to two courses of treatment,each duration of one month,and the efficacy of solid tumors,Karnofsky(KPS)score,tumor marker indexes,clinical symptoms of traditional Chinese medicine(TCM)and the incidence of Osimertinib adverse reactions of the two groups were observed,and SPSS26.0 software was used to statistically analyze,compared the differences before and after treatment and between the two groups,and evaluated the efficacy and safety of Buyang Huanwu decoction combined with osimertinib in the treatment of patients with lung adenocarcinoma BM.Results:(1)Recent Objective Efficacy of Solid Tumors: Both the disease control rate(DCR)and the objective response rate(ORR)of the treatment group were superior to those of the control group.However,statistical analysis indicated that the difference between the two groups was not significant(P>0.05).(2)KPS Score: The KPS scores of both groups showed significant improvement after treatment compared to before treatment,and the difference was significant(P<0.05).However,there was no significant difference in the KPS scores between the two groups after treatment(P>0.05).(3)TCM Syndrome: From the perspective of TCM syndrome score,the treatment group showed more significant improvements in headache,dyspnea and fatigue,speech impediment or aphasia,nausea and vomiting than the control group,and the difference was significant(P<0.05).(4)Serum Tumor Markers: The serum levels of CEA,CYFRA21-1,and SCCA in both groups significantly decreased after treatment compared to before treatment,with a significant difference(P<0.05).However,there was no significant difference in the tumor marker levels between the two groups after treatment(P>0.05).(5)Adverse Reactions: After treatment,the incidence of rash,paronychia,and skin dryness in the treatment group was significantly lower than that in the control group,with a highly significant statistical difference(P<0.05).Although the incidence of other adverse reactions in the treatment group was lower than that in the control group,there was no significant difference between the two groups(P>0.05).Conclusion: The combination of Osimertinib group has a certain effect of inhibiting BM of lung adenocarcinoma,and compared with single-drug Osimertinib,it can effectively relieve the discomfort symptoms of patients and reduce the adverse reactions in the treatment of Osimertinib.